(MedPage Today) — BERLIN — An antibody-drug conjugate targeting Trop2 significantly improved survival outcomes compared with platinum-based chemotherapy in pretreated patients with EGFR-mutated non-small cell lung cancer (NSCLC), a randomized…
Source link : https://www.medpagetoday.com/meetingcoverage/esmo/118028
Author :
Publish date : 2025-10-20 14:57:00
Copyright for syndicated content belongs to the linked Source.
